BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...

BOSTON, May 23, 2025--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test ...

PALO ALTO, Calif. - Guardant Health, Inc. (NASDAQ: GH), a precision oncology company valued at approximately $5 billion, has introduced a complete suite of immunohistochemistry (IHC) testing for key ...

A leading CRO in IHC service and ELISA expertise with over 30 years of innovation, Boster Biological Technology supports global research with trusted antibody solutions. Widely acclaimed for its ...

On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests. This addition will help oncologists identify the ...

The external assessment group (EAG) did a systematic review to identify evidence on the clinical effectiveness and diagnostic accuracy of IHC- and MSI-based testing strategies for detecting Lynch ...

Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project HER2 status was evaluated using ...